Literature DB >> 7848888

Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer.

U Vanhoefer1, H Wilke, H J Weh, M Clemens, A Harstrick, M Stahl, D K Hossfeld, S Seeber.   

Abstract

BACKGROUND: A weekly schedule of a 24-h high-dose 5-FU infusion in combination with folinic acid was investigated as salvage therapy in patients with advanced gastric cancer. PATIENTS AND METHODS: Seventeen patients with progressive disease after chemotherapy were treated with a weekly schedule of 500 mg folinic acid/sqm by i.v. 2-h infusion followed by an i.v. 24-h infusion of 2.6 g 5-FU/sqm times six. Fourteen of the 17 patients (82%) had been pretreated in regimens which included 5-FU/folinic acid i.v. bolus.
RESULTS: Toxicity was mild, with diarrhea, mucositis and nausea; WHO grade III/IV diarrhea was observed in only two patients. Three patients achieved partial remissions (18%; 95% confidence interval: 0%-38%) and 7 patients stable disease (41%; 95% confidence interval: 17%-64%). Their median survival time was five months (range 1.5-10 months) after the onset of salvage therapy.
CONCLUSIONS: This schedule of weekly 24-h infusions of high-dose 5-FU and folinic acid is effective, even in patients pretreated with or resistant to regimens including 5-FU/folinic acid i.v. bolus. Based on these data, it appears that this schedule of high-dose 5-FU/folinic acid in first-line combination chemotherapy merits investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848888     DOI: 10.1093/oxfordjournals.annonc.a059017

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

1.  A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).

Authors:  Tetsuya Hamaguchi; Kuniaki Shirao; Atsushi Ohtsu; Ichinosuke Hyodo; Yasuaki Arai; Hiroya Takiuchi; Hirofumi Fujii; Motoki Yoshida; Hiroshi Saito; Tadamichi Denda; Wasaburo Koizumi; Hiroaki Iwase; Narikazu Boku
Journal:  Gastric Cancer       Date:  2011-04-19       Impact factor: 7.370

2.  Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.

Authors:  H J Kang; H M Chang; T W Kim; M-H Ryu; H J Sohn; J H Yook; S T Oh; B S Kim; J-S Lee; Y-K Kang
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

3.  A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.

Authors:  C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

4.  Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.

Authors:  K H Yeh; S H Yeh; C H Hsu; T M Wang; I F Ma; A L Cheng
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

5.  Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2-mediated autophagy.

Authors:  Lang Fang; Jialun Lv; Zhe Xuan; Bowen Li; Zheng Li; Zhongyuan He; Fengyuan Li; Jianghao Xu; Sen Wang; Yiwen Xia; Tianlu Jiang; Lu Zhang; Linjun Wang; Diancai Zhang; Hao Xu; Li Yang; Zekuan Xu; Weizhi Wang
Journal:  Clin Transl Med       Date:  2022-01

6.  Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.

Authors:  K H Chi; Y Chao; W K Chan; S S Lo; S Y Chen; S H Yen; K Y Chen; C W Wu; S D Lee; W Y Lui
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Authors:  Y Chao; K H Yeh; C J Chang; L T Chen; T Y Chao; M F Wu; C S Chang; J Y Chang; C Y Chung; W Y Kao; R K Hsieh; A L Cheng
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

8.  Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.

Authors:  J T Hartmann; K Oechsle; D Quietzsch; A Wein; R D Hofheinz; F Honecker; O Nehls; C-H Köhne; G Käfer; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.